SEARCH

SEARCH BY CITATION

References

  • 1
    Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360: 115562.
  • 2
    Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab Disp 2002; 30: 969.
  • 3
    Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 41423.
  • 4
    Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental Expression of Human Hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 96574.
  • 5
    Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002; 3: 289309.
  • 6
    Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10: 2734.
  • 7
    Kidd RS, Gallagher SJ, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 8038.
  • 8
    Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 47880.
  • 9
    Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 1019.
  • 10
    Stamer UM, Bayerer B, Wolf S, Hoeft A, Stuber F. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002; 48: 141217.
  • 11
    Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 52234.
  • 12
    Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population. Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193202.
  • 13
    Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40S48S.
  • 14
    Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug ‘Pittsburgh cocktail’ approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997; 62: 36576.
  • 15
    Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype – A major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 155860.
  • 16
    Miners J. CYP2C9 polymorphism. Impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 2002; 12: 912.
  • 17
    Streetman DS, Bertino JSJ, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults. A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187216.
  • 18
    Berthou F, Goasduff T, Lucas D, Dréano Y, Le Bot MH, Ménez JF. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995; 5: 729.
  • 19
    Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JSJ. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the ‘Cooperstown cocktail’. Clin Pharmacol Ther 2000; 68: 37583.
  • 20
    Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001; 70: 45561.
  • 21
    Schellens JHM, Van Der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a ‘cocktail’ study design. J Pharmacol Exp Ther 1989; 249: 63845.
  • 22
    Wandel C, Bocker RH, Bohrer H, DeVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Disp 1998; 26: 11014.
  • 23
    Kalow W. The genetic defect of mephenytoin hydroxylation. Xenobiotica 1986; 16: 37989.
  • 24
    Streetman DS, Kashuba AD, Bertino JSJ, Kulawy R, Rocci MLJ, Nafziger AN. Use of midazolam urinary metabolic ratios for cytochrome P450, 3A (CYP3A) phenotyping. Pharmacogenetics 2001; 11: 34955.
  • 25
    Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Touw DJ, De Zeeuw RA, DeLeij LFJJH. Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events. Br J Clin Pharmacol 2001; 51: 4714.
  • 26
    May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994; 55: 492500.
  • 27
    May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990; 48: 61927.
  • 28
    Lorenzo B, Reidenberg MM. Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol 1989; 28: 2078.
  • 29
    Hamelin BA, Xu K, Vallée F, Manseau L, Richer M, LeBel M. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 1994; 56: 5219.
  • 30
    Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagné P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67: 46677.
  • 31
    Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47: 40311.
  • 32
    St-Hilaire S, Bélanger PM. Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. J Pharm Sci 1989; 78: 8636.
  • 33
    Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. Chromatogr B Biomed Appl, 1996; 686: 2916.
  • 34
    Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, Lertora JJL. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995; 58: 498505.
  • 35
    Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998; 38: 829.
  • 36
    Scott RJ, Palmer J, Lewis IA, Pleasance S. Determination of a ‘GW cocktail’ of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 230519.
  • 37
    Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41: 97580.
  • 38
    Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40: 5318.
  • 39
    Winter HR, Wang Y, Unadkat JD. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Disp 2000; 28: 8658.
  • 40
    Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58: 55666.
  • 41
    Zuidema J, Hilbers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299315.
  • 42
    Soper JW, Chaturvedi AK, Canfield DV. Prevalence of chlorpheniramine in aviation accident pilot fatalities, 1991–96. Aviat Space Environ Med 2000; 71: 12069.
  • 43
    Anderson DT, Fritz KL, Muto T. Distribution of mirtazapine (Remeron) in thirteen postmortem cases. J Anal Toxicol 1999; 23: 5448.
  • 44
    Tingle MD, Mahmud R, Maggs JL, Pirmohamed M, Park BK. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 1997; 283: 81723.
  • 45
    Israili ZH, Cucineil SA, Vaught J, Davis E, Lesser JM, Dayton PG. Studies of the metabolism of dapsone in man and experimental animals. formation of N-hydroxy metabolites. J Pharmacol Exp Ther 1973; 187: 13851.
  • 46
    Labbé L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 42538.
  • 47
    Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 43547.
  • 48
    Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Meth Enzymol 1996; 272: 13945.
  • 49
    Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12: 11119.
  • 50
    Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993; 3: 8693.
  • 51
    Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3: 566.
  • 52
    Adedoyin A, Frye RF, Mauro K, Branch RA. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 1998; 46: 21519.
  • 53
    Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba ADM, Rowland E, Bertino JSJ. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the ‘Cooperstown 5 + 1 cocktail’. Clin Pharmacol Ther 2003; 74: 43747.